Literature DB >> 32321723

What is the true incidence of COVID-19 in patients with rheumatic diseases?

Ennio Giulio Favalli1, Francesca Ingegnoli2,3, Rolando Cimaz3,4, Roberto Caporali2,3.   

Abstract

Entities:  

Keywords:  arthritis; biological therapy; hydroxychloroquine

Year:  2020        PMID： 32321723     DOI： 10.1136/annrheumdis-2020-217615

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  45 in total

1.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2020-06-27       Impact factor: 9.079

Review 2.  What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?

Authors:  Yaşar Keskin; Gökhan Koz; Kemal Nas
Journal:  Eurasian J Med       Date:  2021-06

Review 3.  COVID-19 and rheumatoid arthritis.

Authors:  Kristin M D'Silva; Zachary S Wallace
Journal:  Curr Opin Rheumatol       Date:  2021-05-01       Impact factor: 5.006

4.  Data-Driven and Machine-Learning Methods to Project Coronavirus Disease 2019 Pandemic Trend in Eastern Mediterranean.

Authors:  Wenbo Huang; Shuang Ao; Dan Han; Yuming Liu; Shuang Liu; Yaojiang Huang
Journal:  Front Public Health       Date:  2021-05-13

5.  COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.

Authors:  Amandine Dernoncourt; Jean Schmidt; Pierre Duhaut; Sophie Liabeuf; Valérie Gras-Champel; Kamel Masmoudi; Youssef Bennis; Benjamin Batteux
Journal:  Fundam Clin Pharmacol       Date:  2021-05-25       Impact factor: 2.747

6.  Rheumatic disease management in the Campania region of Italy during the COVID-19 pandemic.

Authors:  Francesco Masini; Klodian Gjeloshi; Roberta Ferrara; Emanuele Pinotti; Giovanna Cuomo
Journal:  Rheumatol Int       Date:  2020-07-14       Impact factor: 2.631

Review 7.  Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.

Authors:  Ilke Coskun Benlidayi; Behice Kurtaran; Emre Tirasci; Rengin Guzel
Journal:  Rheumatol Int       Date:  2020-06-26       Impact factor: 2.631

Review 8.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2021-01-27       Impact factor: 20.999

9.  Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19.

Authors:  Oya Koker; Fatma Gul Demirkan; Gulsah Kayaalp; Figen Cakmak; Ayse Tanatar; Serife Gul Karadag; Hafize Emine Sonmez; Rukiye Omeroglu; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2020-08-02       Impact factor: 2.631

10.  Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up.

Authors:  Rocío-V Gamboa-Cárdenas; Silvia Barzola-Cerrón; Denisse Toledo-Neira; Cristina Reátegui-Sokolova; Víctor Pimentel-Quiroz; Francisco Zevallos-Miranda; Graciela S Alarcón; Manuel Ugarte-Gil
Journal:  Clin Rheumatol       Date:  2021-06-30       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.